For disease classification we used the International Classification of Retinoblastoma (ICRB)5 with a break down as follows: Group A (n=2, 10.5%), group B (n=3, 15.8%), group C (n=9, 47.4%), group D (n=2, 10.5%) and group E (n=3, 15.8%).
Table-2: Treatment Details of Affected Eyes With Respect To ICRB Grade (n=19).
Now with OAC, 90% of the eyes that would be enucleated are getting salvaged.12 Previously the Reese Ellsworth classification was used for retinoblastoma, but now the newer International Classification of Retinoblastoma (ICRB) is being adopted as it can assist in the prediction of chemotherapy success.5 For our analysis, we evaluated the overall globe salvage using a multitude of established treatment modalities at our disposal, including, newer modalities such as OAC and intravitreal chemotherapy, and the overall outcomes based on ICRB.
Delayed diagnosis is one of the primary causes of a high prevalence of retinoblastoma in developing countries and is the most likely cause for a higher disease burden.13 Using ICRB to stratify the eyes in groups, we found that globe salvage was 100% for group A eyes, and 66% for group B.
New modalities such as OAC and Intravitreal Melphalan cause tumour regression leading to globe salvation, even at higher grades of ICRB.
Kucuk ve orta boy tumorlerde (grup B-C ICRB)-sinirli retina alti sivisi varliginda -radyoaktif plak tedavisi ile kontrol saglanabilir.
Genellikle tek tarafli ve ileri evre tumorlerde (grup D-E ICRB) uygulanir (Sekil 4).
(16,17) Kemoreduksiyon, mevcut tumorun (grup B-D ICRB tumorler) fokal tedaviler ile kontrol edilebilecek boyuta getirilmesi anlamina gelmektedir.
Superselektif intra-arteriyel kemoterapi ozellikle tek tarafli ileri evre retinoblastomlarda (grup D-E ICRB) primer tedavi olarak, diger tum standard tedavilerin bagarisiz kaldigi olgularda da sekonder tedavi olarak tercih edilir.